Depot Medroxyprogesterone Injection Market: By Type (Prescriptions & Generic Prescriptions), By End User (Hospital, Pharmacy, and others), By Application (Contraceptive, Hormone Replacement Therapy, Treatment of Endometriosis, and Others), and by Geography

Depot Medroxyprogesterone Injection Market size was valued at USD 800.0 million in 2022 and is poised to grow at a significant CAGR of 4.0% from 2023 - 2029. The injectable progestin-only contraceptive depot medroxyprogesterone acetate (DMPA, often known as Depo-Provera) provides very effective, discreet, three-month reversible contraception. DMPA removes the necessity for daily user activity, action close to sexual intercourse, and partner collaboration. By legalizing the use of injectable contraceptives, developing countries are focusing on lowering infant and mother mortality rates. For example, Haryana was the first state in India to implement the use of injectable contraceptives. The project would start in nine districts across the state, with the injectable available for free at all district hospitals, primary health centers, and community health centers. The United Kingdom authorities authorized Sayana Press in 2015, a three-month progestin-only injectable contraception. The governmental and private partners declared at the London Summit that they would deliver around 12 million doses of Sayana Press to the world's poorest countries by 2020. Injections have traditionally been a popular method of contraception in Sub-Saharan Africa, and the introduction of the Sayana Press injection and Uniject device is expected to increase demand. The all-in-one prefilled injectable device increases access through non-clinical channels while improving safety. The unmet need for contraception remains high. An estimated 225 million women in developing countries would like to delay or prevent pregnancy but are not using any method of contraception. Common reasons include difficulty traveling to health facilities, social barriers, and lack of knowledge about available contraceptive methods. Developing countries are home to more significant population density; it is imperative that governments and local organizations play a pivotal role in creating awareness about family planning, thereby reducing the number of childbirths and population. This could potentially create a market opportunity for the players who offer contraceptive injections at affordable prices. Moreover, the growing demographic dividend in these regions and an increase in fertility rate will positively impact the contraceptive markets in general. It may present a lucrative opportunity for market players with greater market penetration and access to injectable formulations.

Recent Market Developments:

• In January 2019, Drug firm Cipla received the final nod from the US health regulator for its Medroxyprogesterone injectable to prevent pregnancy. The company has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Medroxyprogesterone injectable at 150mg/mL.